tradmap

BIIB Biogen

$196.52 -1.15%

S&P 500 Companies

Held by SPYVOOIVV

Healthcare · Biological Products, (No Diagnostic Substances)

Biogen (BIIB) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $29.0 billion. Shares last traded at $196.52, 4.5% below their 52-week high. Over the past year the stock is up 56.6%. BIIB trades at a price-to-earnings ratio of 22.44, below the Biological Products, (No Diagnostic Substances) median of 22.74. Net profit margin is 13.1%, above the peer median of 6.3%. Revenue grew 2.2% year over year.

Market Cap
$29.0B
Shares Out
147.6M
EPS (TTM)
$18.90
P/E Ratio
10.40
P/S Ratio
2.93
P/B Ratio
1.56
Dividend / Share
Dividend Yield
52-Week High
$205.83
52-Week Low
$121.05
Volume
32,600
Avg Vol (3m)
56,494.952

Performance

1W
-1.70%
1M
+3.13%
3M
+7.12%
6M
+14.66%
YTD
+10.53%
1Y
+56.59%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
52.24
SMA (50)
$190.59
SMA (200)
$174.72
Price vs SMA50
+3.11%
Price vs SMA200
+12.48%
ATR (14)
$5.90

Financials

Revenue
$9.9B
Net Income
$1.3B
Gross Margin
117.7%
Operating Margin
28.7%
Net Margin
13.1%
Return on Equity
6.9%
Return on Assets
4.4%
Current Ratio
3.06
Debt / Equity
0.34
Revenue Growth (YoY)
+2.2%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $2.15 2026-04-29
FY 2025 $8.79 2026-02-06
Q3 2025 $9.14 2025-10-30
Q2 2025 $5.97 2025-07-31
Q1 2026 $1.64 2026-04-29
FY 2025 $11.18 2026-02-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

BIIB vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/E vs peers
22.44 / 22.74 med
-1% discount
P/S vs peers
2.93 / 5.21 med
-44% discount
Net margin vs peers
13.1% / 6.3% med
above median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.